title: Response to: Comment on the implications of external price referencing of pharmaceuticals in Middle East countries.
authors.affiliation: a Syreon Research Institute , Budapest ,  Hungary.|c Department of Health Policy and Health Economics , Eötvös Loránd University , Budapest ,  Hungary.
authors.forename: Zoltán
authors.initials: Z
authors.lastname: Kaló
authors.affiliation: a Syreon Research Institute , Budapest ,  Hungary.|c Department of Health Policy and Health Economics , Eötvös Loránd University , Budapest ,  Hungary.
authors.forename: Zoltán
authors.initials: Z
authors.lastname: Vokó
authors.affiliation: b Novartis Pharma Services AG , Dubai , UAE.
authors.forename: Kasem S
authors.initials: KS
authors.lastname: Akhras
authors.affiliation: d Department of Social Policy , London School of Economics , London , UK.
authors.forename: Panos
authors.initials: P
authors.lastname: Kanavos
mesh_terms: D003132:Commerce / Q000191:economics*; D016527:Drug Costs / Q000706:statistics & numerical data*; D006801:Humans; D004364:Pharmaceutical Preparations / Q000191:economics*
chemical_list: D004364:Pharmaceutical Preparations
keywords: Cross-national price comparison; Middle East countries; external reference pricing; pharmaceutical pricing; price corridor for pharmaceuticals